Literature DB >> 10866320

Epigenetic regulation of the MGMT and hMSH6 DNA repair genes in cells resistant to methylating agents.

A Bearzatto1, M Szadkowski, P Macpherson, J Jiricny, P Karran.   

Abstract

We investigated the relationship between DNA cytosine methylation and the expression of two genes associated with resistance to DNA methylation damage. Variants of RajiMex- cells acquired resistance to N-methyl-N-nitrosourea by either reactivating a previously silent O6-methylguanine-DNA methyltransferase (MGMT) gene or by repressing the hMSH6 mismatch repair gene. DNA sequencing and measurements of mRNA and enzyme levels revealed that MGMT activity was not correlated with methylation of the core MGMT promoter. Treatment with the demethylating agent 5-azadeoxycytidine reduced MGMT mRNA and enzyme levels, indicating that methylation of some nonpromoter sequences may be required for MGMT gene expression. In contrast, both hMSH6 mRNA and protein levels were increased by 5-azadeoxycytidine treatment of an N-methyl-N-nitrosourea-resistant variant that did not express detectable hMSH6, which implies that this gene was transcriptionally silenced by cytosine methylation. This could be substantiated by in vitro modification of the CpG sites in the hMSH6 promoter with restriction methylase M.SssI, which abolished the transcription of a reporter gene under its control in a transient transfection assay. Taken together, our data show that treatment with chemical methylating agents alters gene expression patterns through increased CpG methylation of genomic DNA, and thereby permits the emergence and selection of clones that are resistant to these agents due to increased repair or tolerance of O6-methylguanine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10866320

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Regulation of the human MSH6 gene by the Sp1 transcription factor and alteration of promoter activity and expression by polymorphisms.

Authors:  Isabella Gazzoli; Richard D Kolodner
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

2.  Altered methylation of the DNA repair gene MGMT is associated with neural tube defects.

Authors:  Susanna Tran; Li Wang; Jing Le; Jing Guan; Lihua Wu; Jizhen Zou; Zhen Wang; Jianhua Wang; Fang Wang; Xiaoli Chen; Lingling Cai; Xiaolin Lu; Huizhi Zhao; Jin Guo; Yihua Bao; Xiaoying Zheng; Ting Zhang
Journal:  J Mol Neurosci       Date:  2011-11-19       Impact factor: 3.444

3.  Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment.

Authors:  Daniel P Cahill; Kymberly K Levine; Rebecca A Betensky; Patrick J Codd; Candice A Romany; Linsey B Reavie; Tracy T Batchelor; P Andrew Futreal; Michael R Stratton; William T Curry; A John Iafrate; David N Louis
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

4.  Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma.

Authors:  Jill A Maxwell; Stewart P Johnson; Roger E McLendon; David W Lister; Krystle S Horne; Ahmed Rasheed; Jennifer A Quinn; Francis Ali-Osman; Allan H Friedman; Paul L Modrich; Darell D Bigner; Henry S Friedman
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

5.  Where are we with treatment options after first line in small cell lung cancer?-report of two opposite cases treated with CAPTEM regimen and possible perspectives.

Authors:  Alessio Cortellini; Antonella Dal Mas; Katia Cannita; Guido Collina; Alessandro Parisi; Francesco Pavese; Giampiero Porzio; Lucilla Verna; Corrado Ficorella
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

Review 6.  New drugs in acute myeloid leukemia.

Authors:  Francis J Giles
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

7.  Correlation of clinical features and methylation status of MGMT gene promoter in glioblastomas.

Authors:  J L Blanc; M Wager; J Guilhot; S Kusy; B Bataille; T Chantereau; F Lapierre; C J Larsen; L Karayan-Tapon
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

8.  hMSH2 expression is driven by AP1-dependent regulation through phorbol-ester exposure.

Authors:  Odile Humbert; Ikbel Achour; Dominique Lautier; Guy Laurent; Bernard Salles
Journal:  Nucleic Acids Res       Date:  2003-10-01       Impact factor: 16.971

Review 9.  Genes and pathways driving glioblastomas in humans and murine disease models.

Authors:  Adrian Merlo
Journal:  Neurosurg Rev       Date:  2003-05-29       Impact factor: 3.042

10.  Homogeneous MGMT immunoreactivity correlates with an unmethylated MGMT promoter status in brain metastases of various solid tumors.

Authors:  Barbara Ingold; Peter Schraml; Frank L Heppner; Holger Moch
Journal:  PLoS One       Date:  2009-03-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.